Patents by Inventor Arthur M. Deboeck
Arthur M. Deboeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10709723Abstract: An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.Type: GrantFiled: February 17, 2017Date of Patent: July 14, 2020Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. Deboeck, Phillipe Baudier, Francis Vanderbist
-
Publication number: 20170232029Abstract: An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.Type: ApplicationFiled: February 17, 2017Publication date: August 17, 2017Inventors: ARTHUR M. DEBOECK, PHILLIPE BAUDIER, FRANCIS VANDERBIST
-
Publication number: 20170216178Abstract: A dermatological and/or topical composition, which contains retinaldehyde, and DNA.Type: ApplicationFiled: January 27, 2017Publication date: August 3, 2017Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Gilbert Mouzin
-
Patent number: 9078925Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.Type: GrantFiled: December 18, 2013Date of Patent: July 14, 2015Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DeBoeck, Francis Vanderbist, Cecile Servais, Philippe Baudier
-
Publication number: 20150037414Abstract: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.Type: ApplicationFiled: July 7, 2010Publication date: February 5, 2015Applicant: GALEPHAR M/FInventors: Arthur M. Deboeck, Philippe Baudier, Francis Vanderbist, Antonio Sereno
-
Publication number: 20140107203Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Francis VANDERBIST, Cecile SERVAIS, Philippe BAUDIER
-
Publication number: 20130330404Abstract: An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Type: ApplicationFiled: April 17, 2012Publication date: December 12, 2013Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Francis VANDERBIST, Antonio SERENO
-
Publication number: 20110189269Abstract: The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appear within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less than three times the concentration obtained after 24 hours of said administration.Type: ApplicationFiled: November 18, 2010Publication date: August 4, 2011Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Patent number: 7858118Abstract: An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Type: GrantFiled: April 11, 2002Date of Patent: December 28, 2010Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Publication number: 20030143270Abstract: The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts.Type: ApplicationFiled: April 11, 2002Publication date: July 31, 2003Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Patent number: 5529791Abstract: An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.Type: GrantFiled: September 23, 1994Date of Patent: June 25, 1996Assignee: Galephar P.R., Inc., Ltd.Inventors: Arthur M. Deboeck, Philippe R. Baudier
-
Patent number: 5288505Abstract: An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.Type: GrantFiled: June 26, 1991Date of Patent: February 22, 1994Assignee: Galephar P.R., Inc., Ltd.Inventors: Arthur M. Deboeck, Philippe R. Baudier
-
Patent number: 5036100Abstract: This invention relates to a liquid pharmaceutical preparation for topical use on the skin of patients, said preparation containing indomethacin as active ingredient and dimethylisosorbide and isopropanol as excipients.The preparation according to the invention allows an easy and precise local administration by external application on the skin of a solution of indomethacin in the excipients.Type: GrantFiled: October 5, 1989Date of Patent: July 30, 1991Assignee: Pharlyse S.A. Societe AnonymeInventors: Arthur M. Deboeck, Philippe R. Baudier, Jacques J. Fossion, Paul J. Maes
-
Patent number: 4847282Abstract: Water-soluble acetylcysteine salts, useful as mucolytic agents, consisting of reaction products of acetylcysteine with at least one basic amino-acid, the latter being preferably selected from the group comprising arginine, lysine, histidine, ornithine and glycine.Type: GrantFiled: October 7, 1987Date of Patent: July 11, 1989Assignee: GalepharInventor: Arthur M. Deboeck
-
Patent number: 4699927Abstract: Water-soluble valproic acid salts, consisting of reaction products of valproic acid with at least one basic amino-acid, the latter being preferably selected from the group comprising arginine, lysine, histidine, ornithine and glycine.Type: GrantFiled: May 16, 1986Date of Patent: October 13, 1987Assignee: PharlyseInventor: Arthur M. Deboeck